Restricted accessResearch articleFirst published online 2005-4
Development of an Ion-Pair Reverse-Phase Liquid Chromatographic/Tandem Mass Spectrometry Method for the Determination of an 18-Mer Phosphorothioate Oligonucleotide in Mouse Liver Tissue
A quantitative method for the determination of a partially modified, 2′-ribose alkoxy 18-mer phosphorothioate oligonucleotide in liver tissue has been developed. A liquid:liquid extraction, ion-pair reverse phase chromatographic separation and tandem mass spectrometry were used to achieve a quantitation range of 125 to 10,000 ng g−1 mouse liver tissue. A total cycle time of 5 min was obtained while maintaining separation of three potential impurities. Separations were performed using a Discovery RP-Amide C16, 100 × 2 mm column packed with 5 μm particles. The separation was facilitated by the use of triethylamine (TEA) and hexafluoroisopropanol (HFIP) as ion-pair agents. The method has subsequently been used for the determination of other phosphorothioate oligonucleotides in support of discovery research.
EcksteinF., “Phosphorothioate oligonucleotides: What is their origin and what is unique about them?”, Antisense and Nucleic Acid Drug Dev.10, 117 (2000).
2.
KhuriF.R.KurieJ.M., “Antisense approaches enter the clinic”, Clin. Cancer Res.6, 1607 (2000).
3.
MoniaB.P.HolmlundJ.DorrF.A., “Antisense approaches for the treatment of cancer”, Cancer Investigation18, 635 (2000).
4.
CrookeS.T., “Potential roles of antisense technology in cancer chemotheraphy”, Oncogene19, 6651 (2000).
5.
FlahertyK.T.StevensonJ.P.O'DwyerP.J., “Antisense therapeutics: Lessons from early clinical trials”, Current Opinion in Oncology13, 499 (2001).
6.
JansenB.Zangemeister-WittkeU., “Antisense therapy for cancer—the time of truth”, The Lancet Oncology3, 672 (2002).
7.
CrookeS.T., “An overview of progress in antisense therapeutics”, Antisense and Nucleic Acid Drug Dev.8, 115 (1998).
8.
DeanN.M.ButlerM.MoniaB.P.ManoharanM., in Antisense Drug Technology–Principles, Strategies, and Applications, Ed by CrookeS.T., Marcel Dekker: New York, p. 622 (2001).
9.
CunninghamC.C.HolmlundJ.T.GearyR.S.KwohT.J.DorrA.JohnstonJ.F.MoniaB.NemunaitisJ., “A Phase I Trial of H- ras antisense oligonucleotide ISIS 2503 administered as a continuous intravenous infusion in patients with advanced carcinoma”, Cancer92, 1265 (2001).
10.
BigelowJ.C.ChrinL.R.MathewsL.A.McCormackJ.J., “High-performance liquid chromatographic analysis of phosphorothioate analogues of oligodeoxynucleotides in biological fluids”, J. Chromatogr., B: Biomed. Appl.533, 133 (1990).
11.
LeedsJ.GrahamM.J.TruongL.CumminsL.L., “Quantitation of phosphorothioate oligonucleotides in human plasma”, Anal. Biochem.235, 36 (1996).
12.
MaierM.FritzH.GersterM.SchewitzJ.BayerE., “Quantitation of phosphorothioate oligonucleotides in human blood plasma using a nanoparticle-based method for solid-phase extraction”, Anal. Chem.70, 2197 (1998).
13.
AhmadA.KhanS.DuanL.AndersonL.MansooriB.JiangS.ZhuY.ChienB.AhmadI., “Quantification of 15-mer antisense oligonucleotide in human plasma by liquid chromatography-tandem mass spectrometry”, 50th American Society for Mass Spectrometry, Orlando, FL(2002).
14.
XuK.WilliamsE.WongS.MillerK.GearyR.S.YuR., “Quantitation of antisense oligonucleotides in mouse plasma by LC-MS/MS”, 51st American Society for Mass Spectrometry, Montreal, Canada (2003).
15.
ChenS.QianM.BrennanJ.GalloJ., “Determination of antisense phosphorothioate oligonucleotides and catabolites in biological fluids and tissue extracts using anion-exchange high-performance liquid chromatography and capillary gel electrophoresis”, J. Chromatogr. B.692, 43 (1997).
16.
GriffeyR.H.GreigM.J.GausH.J.LiuK.MonteithD.WinnimanM.CumminsL.L., “Characterization of oligonucleotide metabolism In Vivo via liquid chromatography/electrospray tandem mass spectrometry with a quadrupole ion trap mass spectrometer”, J. Mass Spectrom.32, 305 (1997).
17.
CohenA.S.BourqueA. J.WangB. H.SmisekD.L.BelenkyA., “A nonradioisotope approach to study the in vivo metabolism of phosphorothioate oligonucleotides”, Antisense Nucleic Acid Drug Dev.7, 13 (1997).
18.
GausH.OwensS.WinnimanM.CooperS.CumminsL.L., “On-Line HPLC electrospray mass spectrometry of phosphorothioate oligonucleotide metabolites”, Anal. Chem.69, 313 (1997).
19.
CrainP.F.McCloskeyJ.A., “Applications of mass spectrometry to the characterization of oligonucleotides and nucleic acids”, Current Opinion in Biotechnology9, 25 (1998).
20.
HuberC.OberacherH., “Analysis of nucleic acids by on-line liquid chromatography-mass spectrometry”, Mass Spectrom. Reviews20, 310 (2001).
21.
ApffelA.ChakelJ.A.FischerS.LichtenwalterK.HancockW., “Analysis of oligonucleotides by HPLC-electrospray ionization mass spectrometry”, Anal. Chem.69, 1320 (1997).
22.
ApffelA.ChakelJ.A.FischerS.LichtenwalterK.HancockW., “New procedure for the use of high-performance liquid chromatography–electrospray ionization mass spectrometry for the analysis of nucleotides and oligonucleotides”, J. Chromatogr. A777, 3 (1997).
23.
FountainK.J.GilarM.GeblerJ.C., “Analysis of native and chemically modified oligonucleotides by tandem ion-pair reversed-phase high-performance liquid chromatography/electrospray ionization mass spectrometry”, Rapid Commun. Mass Spectrom.17, 646 (2003).
24.
GearyR.S.MatsonJ.LevinA.A., “A nonradioisotope biomedical assay for intact oligonucleotide and its chain-shortened metabolites used for determination of exposure and elimination half-life of antisense drugs in tissue”, Anal. Biochem.274, 241 (1999).
